REMDESIVIR - Generic Drug Details

What are the generic drug sources for remdesivir and what is the scope of patent protection?

Remdesivir is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Remdesivir has three hundred and forty-three patent family members in forty-nine countries.

One supplier is listed for this compound.

Summary for REMDESIVIR

International Patents:	343
US Patents:	16
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	141
Patent Applications:	8,210
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REMDESIVIR
What excipients (inactive ingredients) are in REMDESIVIR?	REMDESIVIR excipients list
DailyMed Link:	REMDESIVIR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REMDESIVIR

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for REMDESIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	PHASE2
Fred Hutchinson Cancer Center	PHASE2
Fundacin FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promocin de la Salud y la Ciencia	PHASE2

See all REMDESIVIR clinical trials

Pharmacology for REMDESIVIR

Drug Class

SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

Anatomical Therapeutic Chemical (ATC) Classes for REMDESIVIR

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for REMDESIVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VEKLURY	Powder for Injection	remdesivir	100 mg/vial	214787	1	2025-04-22

US Patents and Regulatory Information for REMDESIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes					Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes					Y
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787-002	Oct 22, 2020		DISCN	Yes	No					Y
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787-002	Oct 22, 2020		DISCN	Yes	No					Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes					Y

EU/EMA Drug Approvals for REMDESIVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Veklury	remdesivir	EMEA/H/C/005622Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	Authorised	no	no	no	2020-07-03

International Patents for REMDESIVIR

Country	Patent Number	Title	Estimated Expiration
Denmark	3785717
European Patent Office	4512475	COMPOSITIONS COMPRENANT UN INHIBITEUR DE L'ARN POLYMERASE ET DE LA CYCLODEXTRINE POUR LE TRAITEMENT D'INFECTIONS VIRALES (COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS)
European Patent Office	3651734	COMPOSITIONS COMPRENANT UN INHIBITEUR D'ARN POLYMÉRASE ET DE LA CYCLODEXTRINE POUR LE TRAITEMENT D'INFECTIONS VIRALES (COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS)
Uruguay	37464	MÉTODOS PARA TRATAR INFECCIONES POR EL VIRUS FILOVIRIDAE
Peru	20180202	METODOS PARA TRATAR INFECCIONES POR EL VIRUS FILOVIRIDAE
Denmark	2937350
South Africa	201007713	1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Supplementary Protection Certificates for REMDESIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2595980	53/2020	Austria		PRODUCT NAME: REMDESIVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/20/1459 (MITTEILUNG) 20200703
2595980	2091055-0	Sweden		PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/20/1459 2020-07-03;
2937350	C20200043 00387	Estonia		PRODUCT NAME: REMDESIVIIR;REG NO/DATE: EU/1/20/1459 03.07.2020
2595980	202040053	Slovenia		PRODUCT NAME: REMDESIVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER; NATIONAL AUTHORISATION NUMBER: EU/1/20/1459; DATE OF NATIONAL AUTHORISATION: 20200703; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2595980	2090055-1	Sweden		PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/20/1459, 2020-07-03; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8
2595980	122020000084	Germany		PRODUCT NAME: REMDESIVIR ODER PHARMAZEUTISCH AKZEPTABLES SALZ ODER PHARMAZEUTISCH AKZEPTABLER ESTER DAVON; REGISTRATION NO/DATE: EU/1/20/1459 20200703
2595980	20C1065	France		PRODUCT NAME: REMDESIVIR OU UN SEL OU UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/20/1459 20200703

REMDESIVIR Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Current Market Dynamics for Remdesivir?

Remdesivir is an antiviral drug developed by Gilead Sciences for the treatment of COVID-19. Its market presence and financial trajectory have evolved alongside the pandemic's phases.

Market Penetration and Demand

Since Emergency Use Authorization (EUA) granted by the FDA in May 2020 and subsequent full approval in October 2020, remdesivir became a frontline treatment for hospitalized COVID-19 patients. It chips into the antiviral segment for respiratory illnesses, a sector with estimated sales reaching around $12 billion globally in 2022.[1]

Major healthcare providers in North America, Europe, and Asia include remdesivir in treatment protocols. Global demand peaked in 2021 but has declined as newer therapies and vaccines gained prominence.

Competitive Environment

Remdesivir's primary competitor is dexamethasone, a corticosteroid shown to reduce mortality among severe COVID-19 cases. Other emerging therapies focus on oral antivirals, such as Pfizer's Paxlovid and Merck's Lagevrio (molnupiravir), both administered outside hospital settings.

Stockpiling during the pandemic’s initial wave boosted remdesivir sales temporarily. However, with vaccination coverage increasing and treatments diversifying, its market share diminished from an estimated 70% in mid-2020 to under 20% in 2022.[2]

Supply Chain and Produce Factors

Gilead has ramped up manufacturing capacity, producing approximately 3.3 million doses monthly in 2021.[3] Supply chain disruptions caused occasional shortages early in the pandemic, but current manufacturing is stable.

Policy and Regulatory Impact

Regulatory bodies continue reviewing remdesivir's efficacy for different indications. The European Medicines Agency (EMA) approved remdesivir for hospitalized COVID-19 patients in July 2020; ongoing trials assess whether its use extends to outpatient settings.

Public policy shifts, including funding allocations and inclusion in treatment guidelines, significantly impact market dynamics. The decline in public funding and shifting policies have reduced demand.

How Has the Financial Trajectory of Remdesivir Evolved?

Revenue Performance

Gilead reported remdesivir sales of approximately $5.3 billion in 2021, up from $856 million in 2020.[4] Over 2022, sales declined to about $3 billion, reflecting decreased demand as new therapies gained acceptance and vaccination rates increased.

Cost Structure and Profitability

Gilead's manufacturing costs for remdesivir are approximately 20-25% of sales. Gross margins hover around 85% due to high-margin pharmaceutical products, but overall profitability from remdesivir declined with sales decrease in 2022.

Investment Patterns and R&D

Post-pandemic, Gilead has shifted focus to developing novel antivirals and expanding indications for existing drugs. The company invested roughly $1.5 billion into COVID-19 related R&D through 2022, with a smaller portion allocated directly to remdesivir.

Future Revenue Potential

Potential resurgence depends on:

• Approval for outpatient use
• Efficacy against emerging variants
• Inclusion in new treatment protocols

Clinical trials, such as the PINETREE trial, demonstrate benefits of early intervention with remdesivir, which might extend its application window.[5]

Market Outlook Estimates

Industry analysts project remdesivir sales will stabilize at around $1-2 billion annually over the next five years, primarily driven by stockpiling during health emergencies and niche indications.[6]

What Are the Key Drivers and Risks for Remdesivir's Market and Financial Future?

Drivers

1. Continued use in severe hospitalized cases
2. Expansion into outpatient treatment (pending approval)
3. Strategic stockpiling by governments and hospitals
4. Growing interest in broad-spectrum antiviral agents

Risks

1. Competition from oral antivirals with easier administration
2. Regulatory restrictions if efficacy is questioned
3. Declining COVID-19 case numbers
4. Shift in public health policies away from COVID-specific treatments

Key Takeaways

• Remdesivir's market was highly dynamic during the initial pandemic phases, with peak sales in 2021.
• Since then, demand has declined as other treatments and vaccines have taken precedence.
• Gilead's revenue from remdesivir peaked at over $5 billion but declined to approximately $3 billion in 2022.
• Market growth hinges on regulatory approvals for outpatient use and efficacy against new variants.
• The outlook projects stabilized sales primarily driven by niche and strategic uses rather than widespread adoption.

FAQs

1. Will remdesivir regain market dominance?
Unlikely without new indications or approvals; competition from oral antivirals and vaccines remains fierce.

2. What factors could extend remdesivir’s market lifespan?
Approval for outpatient use, efficacy against variants, and inclusion in combination therapies.

3. How does remdesivir compare financially to its competitors?
It has higher administration costs and logistical complexity relative to oral agents like Paxlovid, impacting profitability and market share.

4. Are there ongoing clinical trials for remdesivir?
Yes; trials evaluate its effectiveness for outpatient use and against newer variants.

5. What is the outlook for remdesivir’s manufacturing capacity?
Manufacturing remains stable, with ongoing capacity adjustments based on demand and strategic considerations.

---

Citations

[1] Evaluate Pharma, 2022. Global antiviral market size.
[2] IQVIA, 2022. COVID-19 antiviral sales data.
[3] Gilead Sciences, 2021. Quarterly reports.
[4] Gilead Sciences, 2022. Annual financial report.
[5] Goldman et al., NEJM, 2021. PINETREE trial results.
[6] Market Research Future, 2022. Antiviral market forecast.